Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 273

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 273
---
 therefore the assets and liabilities of Longevity will be recorded at historical cost with no goodwill or
intangible assets recorded. In connection with the acquisitions of Aegeria, substantially all the fair value is included in in-process
research and development (“IPR&D”) and, as such, the acquisition will be treated as an asset acquisition. Aegeria’s
assets and liabilities will be measured and recognized at their relative fair values as of the transaction date with any value associated
with IPR&D being expensed as there is no alternative future use.

Expected Accounting Treatment of the Business Combination

The Business
Combination will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, FutureTech,
who is the legal acquirer, will be treated as the “acquired” company for accounting purposes and Longevity will be treated
as the accounting acquirer. Accordingly, the Business Combination will be treated as the equivalent of Longevity issuing shares at the
closing of the Business Combination for the net assets of FutureTech as of the closing date, accompanied by a recapitalization. The net
assets of FutureTech will be stated at historical cost, with no goodwill or other intangible assets recorded. Following the Merger will
be a subsidiary of FutureTech. At Closing, FutureTech will change its name to Longevity Biomedical, Inc., and its common stock is expected
to list on Nasdaq under the ticker symbol “LBIO”. Operations prior to the Business Combination will be those of Longevity
in future reports of FutureTech.

| 139 |

Longevity is the accounting acquirer
based on evaluation of the following facts and circumstances:

| ● | Majority of the board of directors is determined by Longevity; |

| ● | Longevity senior management will be the senior management of FutureTech; |

| ● | Longevity’s name will be the name of the combined company; |

| ● | Longevity’s business activities will be the business activities of the combined entity; and |

| ● | Under each redemption scenario, Existing Longevity Stockholders have a majority ownership in FutureTech. |

Vote Required for Approval

This Business
Combination Proposal will be adopted and approved only if at least a majority of the votes cast by holders of our outstanding shares of
FutureTech Common Stock, represented virtually or by proxy and entitled to vote thereon at the Special Meeting, vote “FOR”
the Business Combination Proposal. Assuming a valid quorum is established, a FutureTech stockholder’s